Pathophysiology of Diabetic Gastroparesis (PATODIAG)
Gastroparesis Due to Diabetes Mellitus Type I
About this trial
This is an interventional diagnostic trial for Gastroparesis Due to Diabetes Mellitus Type I focused on measuring gastroparesis
Eligibility Criteria
Inclusion Criteria: Type 1 diabetes age 18-85 Case group: Gastroparesis verified by technetium scintigraphy and a GCSI score ≥ 1.9 Control group: Gastroparesis not confirmed by technetium scintigraphy and score GCSI score < 1.9 Exclusion Criteria: Ongoing cancer treatment or other concurrent illness that will make the patient unable to attend the study on the discretion of the investigator. Recent gastrointestinal surgery Active duodenal/gastric ulcer disease, Diseases in the ventricle or previously complicated upper abdominal surgery Pregnancy or breast feeding Persons who, in the judgement of the investigator, may be unable to follow the protocol. Parkinson disease metoclopramide 48 hours prior to scintigraphy domperidone 48 hours prior to scintigraphy macrolide antibiotics 48 hours prior to scintigraphy anti-cholinergic agents Tricycliv antidepressants Glucagon-like peptide-1 analogues Lithium Diphenhydramine dopamine agonists progesterone, L-dopa calcitonine ocreotide Interferon alfa sucralsulfate botulinum toxin injections (eg, Botox®) by pyloric injection.
Sites / Locations
- Hvidovre University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
cases with gastroparesis
Controls without gastroparesis
patients with a gastroparesis symptom score index (GCSI) of > 1.9 will be considered as cases with gastroparesis and will be subjected to technetium-scintigraphy and gastroscopy with tissuesamples from antrum and fundus and bloodsamples of glucosemetabolism
patients with a gastroparesis symptom score index (GCSI) of < 1.9 will be considered as controls without gastroparesis and will be subjected to technetium-scintigraphy and gastroscopy with tissuesamples from antrum and fundus and bloodsamples of glucosemetabolism